The role of endothelin and prostacyclin on recombinant erythropoietin- ? induced hypertension in hemodialysis patients

Basit Öğe Kaydı
dc.contributor.authorTürkmen, Kültigin
dc.contributor.authorErdur, Fatih Mehmet
dc.contributor.authorDalmaz, Mahmut
dc.contributor.authorYeksan, Mehdi
dc.contributor.authorAkkuş, İdris
dc.contributor.authorTürk, Süleyman
dc.date.accessioned2020-03-26T18:48:20Z
dc.date.available2020-03-26T18:48:20Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractOBJECTIVE: Recombinant human erythropoietin (r-HuEPO) was found to be associated with increased blood pressure in hemodialysis (HD) patients. Plasma endothelin-1(ET-1) was reported to be increased during treatment with r-huEPO in HD patients. Prostacyclin (PGI2) was found to be associated with the reduction in vascular resistance. We aimed to determine the role of ET-1 and PGI2 on r-huEPO-induced hypertension in HD patients. MATERIAL and Methods: 43 HD patients (19 females, 24 males) were randomly assigned to groups. Group 1 (n=15) consisted of patients receiving r-HuEPO-? subcutaneously after each dialysis session for 6 to 42 months. Group 2 (n=15, control group) consisted of patients who did not receive any r-huEPO and group 3 (n=13) consisted of patients who received r-huEPO-? subcutaneously after each dialysis session for 12 weeks. Plasma ET-1,2 and 6-keto-PGF1-? were measured. Results : There were no differences in terms of ET-1,2 and 6-keto-PGF1-?, systolic and diastolic BP and hematocrit levels in group 1 and group 2 patients. However, in group 3 patients, hematocrit, plasma ET1,2 and 6-keto PGF1-? levels were significantly elevated after 12 weeks of rHuEPO treatment. Conclusion: We showed that ET-1.2 and 6-keto-PGF1-? levels were found to be significantly increased with 12 weeks of rHu-EPO therapy in HD patients.en_US
dc.identifier.doi10.5262/tndt.2013.1001.13en_US
dc.identifier.endpage94en_US
dc.identifier.issn1300-7718en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage89en_US
dc.identifier.urihttps://dx.doi.org/10.5262/tndt.2013.1001.13
dc.identifier.urihttps://hdl.handle.net/20.500.12395/30225
dc.identifier.volume22en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Nephrology, Dialysis and Transplantation Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectEndothelinen_US
dc.subjectErythropoietinen_US
dc.subjectHemodialysisen_US
dc.subjectHypertensionen_US
dc.subjectProstacyclinen_US
dc.titleThe role of endothelin and prostacyclin on recombinant erythropoietin- ? induced hypertension in hemodialysis patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu